- Home
- RHE vs PCSA Comparison
RHE vs PCSA Comparison
Compare RHE & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RHE
- PCSA
- Stock Information
- Founded
- RHE 1988
- PCSA 2011
- Country
- RHE United States
- PCSA United States
- Employees
- RHE N/A
- PCSA N/A
- Industry
- RHE Real Estate
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- RHE Real Estate
- PCSA Health Care
- Exchange
- RHE Nasdaq
- PCSA Nasdaq
- Market Cap
- RHE 2.9M
- PCSA 3.1M
- IPO Year
- RHE 2006
- PCSA N/A
- Fundamental
- Price
- RHE $2.29
- PCSA $0.82
- Analyst Decision
- RHE
- PCSA Strong Buy
- Analyst Count
- RHE 0
- PCSA 2
- Target Price
- RHE N/A
- PCSA $5.00
- AVG Volume (30 Days)
- RHE 2.2M
- PCSA 87.9K
- Earning Date
- RHE 11-19-2024
- PCSA 10-30-2024
- Dividend Yield
- RHE N/A
- PCSA N/A
- EPS Growth
- RHE N/A
- PCSA N/A
- EPS
- RHE N/A
- PCSA N/A
- Revenue
- RHE $15,753,000.00
- PCSA N/A
- Revenue This Year
- RHE N/A
- PCSA N/A
- Revenue Next Year
- RHE N/A
- PCSA N/A
- P/E Ratio
- RHE N/A
- PCSA N/A
- Revenue Growth
- RHE N/A
- PCSA N/A
- 52 Week Low
- RHE $1.13
- PCSA $0.80
- 52 Week High
- RHE $6.80
- PCSA $7.14
- Technical
- Relative Strength Index (RSI)
- RHE 57.17
- PCSA 39.52
- Support Level
- RHE $1.78
- PCSA $0.80
- Resistance Level
- RHE $2.58
- PCSA $0.91
- Average True Range (ATR)
- RHE 0.53
- PCSA 0.08
- MACD
- RHE 0.02
- PCSA -0.00
- Stochastic Oscillator
- RHE 16.33
- PCSA 7.82
About RHE Regional Health Properties Inc.
Regional Health Properties Inc is a self-managed healthcare real estate investment company that invests in real estate purposed for senior living and long-term healthcare through facility lease and sub-lease transactions. It has two reportable segments real estate segment and the healthcare services segment. It derives the majority of its revenue from the healthcare services segment. Its portfolio of properties is diversified across various states, with concentrations in Georgia and Ohio.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).